BetterLife Pharma (BETRF) Total Current Liabilities (2011 - 2026)

BetterLife Pharma has reported Total Current Liabilities for 16 years, with the latest figure at $4.9 million in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 10.19% year-over-year to $4.9 million in Q2 2026; TTM through Apr 2026 was $4.9 million, a 10.19% increase from a year earlier, with the FY2026 full-year figure at $4.8 million, down 12.35% from the prior year.
• Total Current Liabilities was $4.9 million for Q2 2026 at BetterLife Pharma, up from $4.8 million in the prior quarter.
• The five-year high for Total Current Liabilities was $5.4 million in Q1 2024, with the low at $3.3 million in Q1 2022.
• Average Total Current Liabilities over 5 years is $4.7 million, with a median of $4.7 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities slipped 27.98% in 2022, then surged 61.88% in 2023.
• Over 5 years, Total Current Liabilities stood at $4.7 million in 2022, then dropped by 0.91% to $4.7 million in 2023, then retreated by 8.65% to $4.3 million in 2024, then increased by 1.35% to $4.4 million in 2025, then rose by 11.33% to $4.9 million in 2026.
• The last three Total Current Liabilities figures came in at $4.9 million (Q2 2026), $4.8 million (Q1 2026), and $4.4 million (Q3 2025), per Business Quant data.